Literature DB >> 1687015

Renal tubular transport of morphine, morphine-6-glucuronide, and morphine-3-glucuronide in the isolated perfused rat kidney.

J T Van Crugten1, B C Sallustio, R L Nation, A A Somogyi.   

Abstract

The isolated perfused rat kidney was used to examine the renal handling of morphine and its inactive metabolite morphine-3-glucuronide (M3G), and active metabolite morphine-6-glucuronide (M6G). The kidneys were perfused with Krebs-Henseleit buffer (pH 7.4) containing albumin, glucose, and amino acids, and drug concentrations were measured by high performance liquid chromatography. There was no conversion of morphine to the glucuronides or deconjugation of M3G or M6G. At an initial morphine concentration of 100 ng/ml, the unbound renal clearance to glomerular filtration rate ratio (CLur/GFR) was 5.5 +/- 3.2 (mean +/- SD), indicating that net tubular secretion of morphine occurred. In the presence of M3G (2000 ng/ml) and M6G (500 ng/ml) this Clur/GFR ratio was elevated to 17.3 +/- 4.8 (p less than .001), which implicates an interaction between these compounds at an active reabsorption transport system. The CLur/GFR ratio for M3G at 2000 ng/ml was 0.90 +/- 0.04, indicating the possibility of a small component of tubular reabsorption, and this ratio was not significantly altered in the presence of morphine and M6G. M6G was reabsorbed, probably actively, to a greater extent than M3G, with an initial CLur/GFR ratio of 0.67 +/- 0.04, which was not affected when morphine and M3G were coadministered. These data demonstrate an unusual phenomenon in that the glucuronide metabolites, which are larger and less lipophilic than the parent drug morphine, undergo net tubular reabsorption. The renal handling of morphine is a complex combination of glomerular filtration, active tubular secretion, and possibly active reabsorption.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1687015

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

1.  Blood-brain distribution of morphine-6-glucuronide in sheep.

Authors:  H H Villesen; D J R Foster; R N Upton; L L Christrup; A A Somogyi; A Martinez; C Grant
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

2.  Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates.

Authors:  Jeroen W B Peters; Brian J Anderson; Sinno H P Simons; Donald R A Uges; Dick Tibboel
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium.

Authors:  J Huwyler; J Drewe; C Klusemann; G Fricker
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

4.  Morphine blood-brain barrier transport is influenced by probenecid co-administration.

Authors:  Karin Tunblad; E Niclas Jonsson; Margareta Hammarlund-Udenaes
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

Review 5.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Rectal administration of nicomorphine in patients improves biological availability of morphine and its glucuronide conjugates.

Authors:  P M Koopman-Kimenai; T B Vree; L H Booij; R Dirksen
Journal:  Pharm World Sci       Date:  1994-12-02

7.  Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine.

Authors:  A A Somogyi; R L Nation; C Olweny; P Tsirgiotis; J van Crugten; R W Milne; J F Cleary; C Danz; F Bochner
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

8.  Heroin crystal nephropathy.

Authors:  Josef Edrik Keith Bautista; Basma Merhi; Oliver Gregory; Susie Hu; Kammi Henriksen; Reginald Gohh
Journal:  Clin Kidney J       Date:  2015-03-31

9.  The pharmacokinetics of the interstitial space in humans.

Authors:  David G Levitt
Journal:  BMC Clin Pharmacol       Date:  2003-07-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.